How convincing is the evidence that light therapy actually works? The pace of research on bright light therapy has accelerated over the last few years, and recently, two meta-analyses of this research have been published, one in the American Journal of Psychiatry, and the other in the web-based Cochrane Library.
Read More
f you haven’t started hearing about the “benefits” of blue light therapy yet, you will soon. Blue light boosters argue that it is more effective than white light, and that it is the therapeutic ingredient of standard white light that eases seasonal depression.
Read More
Since I had never actually seen a light box in the flesh, I asked some of the larger companies to send me samples for a “review”—not for efficacy but for such qualities as convenience, asthetics, pleasantness, etc…
Read More
Wellbutrin XL was approved for the prevention of Seasonal Affective Disorder (SAD), based on the results three studies in which over 1,000 patients with SAD (but who were well at study entry) were randomly assigned to either Wellbutrin XL 150 to 300 mg QD or placebo. Do insurance companies pay for light boxes? Many of them do … or at least they say they do!
Read More
Dr. Aiken is the Editor in Chief of The Carlat Psychiatry Report; director of the Mood Treatment Center in North Carolina, where he maintains a private practice combining medication and therapy along with evidence-based complementary and alternative treatments; and Assistant Professor NYU Langone Department of Psychiatry. He has worked as a research assistant at the NIMH and a sub-investigator on clinical trials, and conducts research on a shoestring budget out of his private practice. Follow him on Twitter and find him on LinkedIn.
KarXT (Cobenfy) is the first antipsychotic that doesn’t block dopamine. We trace the origins of this new drug to a South Asian herb used for over 5,000 years, up to the three...